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Introduction: Leber congenital am
aurosis (LCA) is a group of recessively inherited, early infantile-onset, severe rod-cone dystrophies that can 
result from
 defects in at least 25 genes, including RPE65, CEP290, RDH12, AIPL1 and GUCY2D. The possibility of benefit is offered by 
therapeutic intervention to provide the functional gene that is otherw
ise lacking. Areas Covered: W
e searched PubM





entary: Clinical trials of gene therapy for LCA ow
ing to defects in RPE65 have dem
onstrated benefit w
ith im
proved function of rod 




photoreceptor cell function can be protected by appropriate gene delivery at an early stage of the disease.  Clinical trials of gene therapy for 
LCA ow




aurosis, LCA, LCA2, RPE65 associated LCA, gene therapy, clinical trials 
 Introduction 





as first described in 1869 by Theodore Leber. LCA is now
 used to define a group of recessively inherited, 
severe, early infantile-onset, rod-cone dystrophies[1]. LCA accounts for greater than 5%
 of inherited retinal disease[2], w
ith a prevalence of 
betw
een 1 in 33,000[2] and 1 in 81,000[3]. LCA classically presents at birth or in early infancy w




pupillary responses, and undetectable responses to full-field electroretinography (ERG). How
ever, the condition dem
onstrates significant 
phenotypic variability and m
ay present later in infancy or early childhood as an ‘early onset severe retinal dystrophy’ (EOSRD) w
ith im
paired 
but residual visual function and highly attenuated but detectable ERG responses.[1] There is significant overlap betw
een the m
olecular causes 
of classical LCA and EOSRD, w
ith som
e genes im
plicated in both clinical phenotypes. To date, defects in 25 identified genes account for 
approxim
ately 70-80%
 of affected individuals.[1] Since the condition is typically the consequence of lack-of-function m
utations, it has the 
potential to benefit from






utations by provision of the norm
al gene to the cells in w
hich it is required.[4] The therapeutic gene, typically delivered using 
a viral vector, is utilised by the transcriptional m
achinery of the target cell to generate the norm
al gene product that is otherw
ise lacking. 
Vector-m
ediated gene delivery can also be used to establish sustained local expression of proteins that m
ay be neuroprotective.[5] Alternative 
gene therapy techniques can be used to suppress the undesirable expression of a harm






ultaneous provision of the norm
al gene.[6,7] M
ore recently, gene editing strategies to correct harm
ful 




utations in endogenous genes, and anti-sense oligonucleotide m
ediated exon skipping to m
itigate their im
pact, are also being 
investigated.[8,9] 
 The retina has specific advantages as a target organ for gene therapy. The transparency of the ocular m
edia provides accessibility for 
m
icrosurgical delivery of vector suspension to the retina under direct visualisation and for high-resolution optical im
aging to assess its im
pact. 






ing to the contained nature and 
com
partm
entalisation of the intraocular tissues. The intraocular environm
ent provides the retina w




helps protect against im
m
une responses that could adversely affect retinal function and lim
it expression of the therapeutic gene. Since 
inherited retinal diseases such as LCA typically cause bilateral disease w
ith a significant degree of sym
m
etry, the untreated contralateral eye 
offers a valuable control for natural history, intra-individual variability in perform
ance and learning effects. 
 For gene transfer to retinal cells in LCA, m
ost clinical applications currently use recom
binant adeno-associated virus (AAV) or lentivirus vectors. 
AAV is a sm
all, non-pathogenic single stranded DNA virus w
idely used for gene delivery in inherited retinal diseases. AAV vectors can m
ediate 
efficient and sustained transduction of photoreceptor cells, retinal pigm
ent epithelium
 (RPE), and ganglion cells. First-generation AAV2 vectors 
are lim
ited by relatively slow
 onset of expression and sm
all capacity (4.7 kB).[10] How




entary vectors and novel variants by rational design and/or directed evolution, have provided a broad range of 





ore rapid expression and w
ider cell tropism
s.[11,12] M
easures to address the lim
ited capacity include dual AAV vector 
strategies in w
hich a large gene delivered in com
ponent parts by m
ultiple AAV vectors is reconstituted by splicing.[13] Lentiviral vectors have 
substantially greater capacity (approxim
ately 8 kB) than AAV and can naturally accom
m
odate larger genes. Lentiviral vectors m
ediate efficient 
transduction that is typically lim
ited to RPE cells.[14] 
 Since defects in genes involved in phototransduction or the visual cycle account for m
any form
s of LCA, photoreceptors and RPE cells are 
im
portant target populations for gene therapy. Viral vectors deliver genes to these cells m
ost efficiently w
hen the vector is placed in direct 
contact by injecting the vector suspension into the potential space betw
een the RPE and the overlying photoreceptor cell layer. Injection into 
this subretinal space is typically perform
ed using a fine cannula that is advanced through the sclera anteriorly, across the vitreous cavity and 
through the neuroretina. Injection into this site generates a bleb of vector suspension that tem
porarily separates the neurosensory retina from
 
the underlying RPE, before it is absorbed over a period of hours or days.  
 Although subretinal adm
inistration appears generally w
ell-tolerated, a risk of harm
 from
 consequent thinning of the outer neurosensory retina 
is recognised.[15,16] The safety of subretinal adm
inistration m
ay be im
proved by appropriate control of the pressure and flow
 rate of 
injection, and the height and duration of neurosensory separation. Injection of vector suspension into the vitreous cavity is a less invasive 
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alternative to subretinal adm
inistration. Using current vector system




 because vector penetration across the inner retina is lim
ited, but novel capsid variants such as AAV7M
8 offer the 
potential for greater vector penetration and m
ore efficient gene delivery.[17]   
 W




une responses, vectors injected into the vitreous 
cavity can generate deleterious im
m
une responses[18] possibly ow
ing to flow
 of vector particles w
ithin the intraocular fluid com
partm
ents 
and via the outflow
 pathw
ays to the system
ic circulation. M
easures to protect against intraocular inflam
m
ation, w
hich presents a risk of harm
 
and could lim




edication around the 
period of vector adm
inistration. 
 RPE65-associated LCA 
 M
utations in the gene RPE65 account for approxim
ately 5-10%
 of LCA.[19] RPE65 encodes a 65kD retinoid isom
erase that is expressed in the 
RPE and is essential for the production of 11-cis retinal, a critical com
ponent of the retinoid (visual) cycle.[20,21] A lack of functional RPE65 
results in deficiency of 11-cis retinal such that rod photoreceptor cells are unable to respond to light, causing profound night blindness from
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birth.[1]   Cone photoreceptor cell function can be relatively preserved initially because cones have access to 11-cis–retinaldehyde 
chrom
ophore through an alternative retinoid pathw
ay.[22] How
ever, cone-m
ediated vision deteriorates during childhood and early adulthood 
ow
ing to progressive degeneration of the retina that involves both rod and cone photoreceptor cells.  
 Subretinal injection of AAV-vectors encoding the cDNA for RPE65 can im
prove visual function in rodent m
odels of RPE65-LCA, and in the 
Sw
edish Briard dog, w
hich has a naturally occurring m
utation in RPE65. [23] In the Rpe65 knock-out  m
ouse, gene therapy not only im
proves 
rod photoreceptor function but also preserves cone function and protects against degeneration.[24,25] In the naturally occurring Rpe65-
deficient Rd12 m
ouse gene therapy can im
prove rhodopsin levels, im
prove ERG responses dose-dependently to near norm
al levels[26]  and 
im
prove dim
-light vision.[27]  In affected dogs, [28] AAV-m
ediated expression of RPE65 can result in im
proved responses on ERG, pupillom
etry 
and flash-evoked cortical potentials in the dark-adapted state, w
ith functional im
provem
ents sustained for as long as 10 years [23] and 
preservation of outer nuclear layer thickness evident on OCT scanning.[29]  
 In early-phase clinical trials in hum
ans w
ith RPE65-LCA, gene therapy has resulted in im




ents in photoreceptor function in affected individuals have been relatively m
odest com




hen retinal degeneration is less advanced, and the durability of benefit can be lim
ited by progressive retinal degeneration.[31-34] In 
Gene therapy for Leber congenital am
aurosis 
7 
one trial of subretinal adm
inistration of an AAV2/2 vector, im
provem
ents in retinal sensitivity, dark-adapted perim
etry and vision-guided 
m
obility w
ere evident in 6 of 12 participants but w
ere not sustained, w




ere noted in the other clinical trials. In a separate trial variable im
provem
ents in visual function localised to the treated area of 
retina w
ere evident in all 15 participants but the benefit declined over tim
e.[34,35] A phase III trial of subretinal adm
inistration of an AAV2/2 
vector has also reported benefit at 1 year, reaching its prim
ary endpoint for efficacy w
ith im
proved perform




obility.[36] This product, voretingene neparvovec (Luxturna, Spark Therapeutics Inc) has recently been approved  by the FDA for 
the treatm
ent of RPE65-associated retinopathy. Findings of relatively m
odest efficacy and lim
ited durability of benefit in other studies suggest 
that current vectors m
ay not fully m
eet the dem
and for RPE65 in hum
ans.[32] An optim
ized AAV2/5 vector carrying an optim
ized hRPE65 
prom
oter and a codon-optim
ised hRPE65 gene is at least 300-fold m
ore potent in m
ouse m
odels.[15,37] and is the subject of a phase I/II 
clinical trial (clinicaltrials.gov: NCT02781480). 
 CEP290-associated LCA 
 CEP290 encodes a centrosom
al protein involved in trafficking through the connecting cilia of photoreceptor cells. M
utations in CEP290 account 
for 15- 20%
 of LCA and represent one of the m
ost com
m
on causes. At 7.5kb, the full-length gene exceeds the capacity of AAV vectors but can 





odated by lentiviral vectors. Given the lack of suitable anim
al m
odels, gene therapy based intervention for CEP290 associated LCA 
has been explored in vitro; transduction of patient-specific induced pluripotent stem
 cell-derived photoreceptor precursor cells rescues the 
cellular phenotype.[38] Alternative m
olecular therapeutic strategies focus on the com
m
on deep intronic CEP290 sequence variant, w
hich 
creates a strong splice donor site that leads to the insertion of a cryptic exon encoding a prem
ature stop codon. Techniques include anti-sense 
oligonucleotide m
ediated exon skipping to abrogate the disease-causing variant, and correction of the splice defect using CRISPR/Cas9-
m
ediated gene editing.[8,9] A clinical trial investigating the safety and tolerability of intravitreal RNA antisense oligonucleotide is ongoing 
(clinicaltrials.gov: NCT03140969). 
 AIPL1-associated LCA 
 Aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) is a m
olecular chaperone of phosphodiesterase 6, w
hich m
ediates 
phototransduction in both rod- and cone- photoreceptors. M
utations in AIPL1 cause a particularly severe, rapidly progressive disorder, w
hich 
accounts for less than 5%
 of LCA.[19] Affected children have severe sight im
pairm
ent in early infancy, and rapid retinal degeneration. Although 
the outcom
e is very poor, som
e preservation of retinal structure during infancy indicates a w
indow
 of opportunity for intervention by gene 
replacem
ent therapy,[39] w
ith proof of principle dem
onstrated using an AAV2/8 vector in a rodent m
odel of the disorder.[40]  
Gene therapy for Leber congenital am
aurosis 
9 
 RDH12-associated LCA 
 RDH12 encodes a broad specificity aldehyde reductase localised in photoreceptor inner segm
ents. The protein is not essential in the visual 
cycle, but is believed to protect against toxic accum
ulation of all-trans-retinal under persistent illum
ination.[41] Disease-causing sequence 
variants in RDH12 account for approxim
ately 10%
 of LCA/EOSRD.[19,42] AAV2/8-vector-m
ediated RDH12 gene replacem
ent therapy in Rdh12 
knockout m
ice indicates the potential for benefit in affected hum
ans.[43] 
 GUCY2D-associated LCA 
 Retinal guanylate cyclase-1 (GUCY2D) is essential in photoreceptor cells for tim
ely recovery from
 photoexcitation. M
utations in the GUCY2D 
gene account for 10-20%
 of LCA. Photoreceptor architecture in GUCY2D-LCA is relatively w
ell preserved[44]  and preclinical studies of gene 
augm
entation therapy in anim
al m
odels have dem
onstrated benefit. HIV1-based lentiviral vector in ovo im
proves optokinetic reflexes and 
volitional visual behaviour in a chicken m
odel.[45] In the GC1 knock-out m
ouse, both AAV serotype 5 (AAV5) and AAV8 vectors can protect 
retinal function and preserve of cone photoreceptor cells.[46-48] In the GC1/GC2 double knock out m
ouse, the tyrosine capsid m
utant 
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AAV8(Y733F) restores both cone and rod- m
ediated vision. [49] Proof of principle in experim
ental m
odels and relative preservation of 
photoreceptor cells in affected hum
ans suggest that affected individuals stand to benefit from
 gene augm
entation therapy.  
 RPGRIP1-associated LCA 
 Retinitis pigm
entosa GTPase regulator (RPGR) is anchored in the connecting cila of photoreceptor cells by RPGR-interacting protein (RPGRIP). 
M
utations in RPGRIP1 account for about 5 %
 of LCA.[50,51] In contrast to other form
s of LCA, RPGRIP1-associated LCA appears to be relatively 
non-progressive, follow
ing an initial rapid decline in visual function.[52] Furtherm
ore, photoreceptor structure is preserved despite 
deterioration in visual function.[53] In the RPGRIP1 knockout m
ouse and in a m
ouse m





ediated expression of RPGRIP1 can protect photoreceptor cells against degeneration and preserve retinal 
function.[54,55] In a canine m
odel carrying a spontaneous hom
ozygous RPGRIP1 ins44 m
utation, subretinal injection of AAV vector expressing 
canine cDNA an under the control of a hum
an rhodopsin kinase prom
oter im
proves photoreceptor function for as long as 24 m
onths.[56]  
These findings suggest the potential for individuals affected by RPGRIP1-LCA to benefit  from








 of gene therapy for LCA is to protect affected children from
 disabling im
pairm
ent of sight by correcting the genetic defect responsible. 
In the last 20 years, progress in the field has led from
 proof of concept of retinal gene transfer to licensing of the first approved treatm
ent. The 




ent and provide durable benefit in the long term
. This w
ill depend on tim
ely 




 the surgical procedure and im
m
une responses. The developm
ent of better validated outcom
e m
easures of retinal function 
in children is required to provide relevant endpoints for clinical trials and to estim




ent of retinal structure by w
ide-field high-resolution optim
al im
aging is required to enable optim
al targeting of vector, and to provide a 
potentially valuable surrogate outcom
e indicating the potential for protection of sight. Gene therapies developed for children w
ith LCA, like 
those for other rare diseases, w
ill need to be m





es of clinical trials of gene therapy for LCA- RPE65 have led to the recent licensing of a gene therapy product for this indication. 
The results of ongoing trials w
ill help define the potential w
indow
 of opportunity for effective intervention. Early intervention, w
hile retinal 
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structure and cortical plasticity are relatively preserved, is likely to offer the best outcom




ill support clinical trials of gene therapy for other form
s of LCA. Further developm
ents in vector design and delivery w
ill provide 
greater efficiency and safety of gene transfer. Rapid reliable assessm
ent of outcom
es w
ill be accelerated by optim
isation of clinical trial design.  




aurosis (LCA) is a group of severe recessively-inherited infantile-onset rod-cone dystrophies that result from
 
m
utations in at least 25 genes. 
• 
In rodent and canine experim
ental m
odels, gene augm
entation therapy for several causative gene defects can im
prove retinal function 
and protect against retinal degeneration. 
• 




ent in aspects of sight. The m
agnitude and durability 
of benefit in hum
ans m
ay be lim
ited by established degeneration and the potency of current vectors.  
• 
A clinical trial of anti-sense oligonucleotide m
ediated exon skipping for CEP290-LCA is ongoing. 
• 
Efficacy of gene therapy in experim
ental m
odels of LCA ow
ing to m
utations in AIPL1, RDH12, GUCY2D and RPGRIP support its 
application in affected hum
ans. 





ents in vector design and delivery w
ill provide greater efficiency and safety of gene transfer. 
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m
ary of clinical trials for LCA. *RNA antisense oligonucleotides are adm
inistered w
ithout a vector.
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